By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – MDxHealth said today that Celldex Therapeutics will use its epigenetic MGMT test during recruitment of patients for a Phase III clinical study of Celldex's immunotherapeutic vaccine, rindopepimut, in newly diagnosed glioblastoma multiforme.

The study is expected to recruit 374 patients with newly diagnosed EGFRvIII-expressing GBM, an aggressive form of brain cancer, following gross total resection at more than 150 global clinical sites.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: caution urged in use of gene drives, and more.

NIH's Sally Rockey examines the tapped and untapped potential of the NIH peer reviewer pool.

PLOS Biology has asked researchers how they envision the future of genetics and genomics.

Representative Lamar Smith brings back a provision to require the National Science Foundation to certify that each study it funds is "in the national interest."

Sep
17
Sponsored by
Omicia

This online seminar will provide examples of how commercial and hospital-affiliated clinical labs are successfully developing and deploying high-throughput next-generation sequencing-based testing services for genetic diseases. 

Oct
15
Sponsored by
Parabase

This webinar will discuss the benefits of a rapid targeted next-generation sequencing (TNGS) panel, using dried blood spots, for second-tier newborn metabolic and hearing loss screening and its immediate utility for high-risk diagnostic testing in the neonatal intensive care unit.